NEI Research News

Using atomic force microscopy, researchers at Doheny Eye Institute, an affiliate of University of California Los Angeles, discovered retinal capillary stiffening in diabetic mice that is causally linked to the development of retinopathy

NEI-funded investigators at Washington University in St. Louis discovered a potential new treatment approach to diabetic retinopathy, one of the most common causes of vision loss in the U.S.

Using a technique they developed for studying eye fluid, Stanford Medicine researchers and their collaborators have found a way to measure ocular aging, opening avenues for treatment of numerous eye diseases.

Researchers found that diabetes, age-related health conditions and other metabolic disorders can lead to a buildup of cholesterol in the retina, which could contribute to diabetic retinopathy.

Researchers have successfully transplanted human microglia into mouse retina to create a model for studying eye disease treatments, such as diabetic retinopathy, glaucoma and age-related macular degeneration.

Cedars-Sinai researchers uncover disease-related changes to the cornea and propose potential therapeutic approaches to correct diabetic wound healing.

Researchers from Johns Hopkins Medicine show that experimental drug may prevent or slow vision loss in people with diabetic retinopathy, a complication of diabetes.

In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).

UVA Health scientists have discovered an unknown contributor to harmful blood vessel growth in the eye that could lead to new treatments for blinding macular degeneration and other common causes of vision loss.

While early treatment of diabetes-related eye disease slowed progression to severe disease, it did not improve visual acuity compared with treating more severe disease once it developed, according to a clinical study from the DRCR Retina Network.